SMT201600102B - Tritoqualina per l’uso nel trattamento della fibrosi cistica - Google Patents

Tritoqualina per l’uso nel trattamento della fibrosi cistica

Info

Publication number
SMT201600102B
SMT201600102B SM201600102T SM201600102T SMT201600102B SM T201600102 B SMT201600102 B SM T201600102B SM 201600102 T SM201600102 T SM 201600102T SM 201600102 T SM201600102 T SM 201600102T SM T201600102 B SMT201600102 B SM T201600102B
Authority
SM
San Marino
Prior art keywords
tritoqualina
treatment
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
SM201600102T
Other languages
English (en)
Inventor
Dominique Costantini
Original Assignee
Orphan Synergy Europ Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Synergy Europ Pharma filed Critical Orphan Synergy Europ Pharma
Publication of SMT201600102B publication Critical patent/SMT201600102B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201600102T 2012-04-30 2016-04-12 Tritoqualina per l’uso nel trattamento della fibrosi cistica SMT201600102B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305487.6A EP2659890A1 (en) 2012-04-30 2012-04-30 Methods and compositions for the treatment of fibrosis
PCT/EP2013/058158 WO2013164204A1 (en) 2012-04-30 2013-04-19 Tritoqualine for use in the treatment of cystic fibrosis
EP13718559.1A EP2844253B1 (en) 2012-04-30 2013-04-19 Tritoqualine for use in the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
SMT201600102B true SMT201600102B (it) 2016-07-01

Family

ID=48184183

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600102T SMT201600102B (it) 2012-04-30 2016-04-12 Tritoqualina per l’uso nel trattamento della fibrosi cistica

Country Status (14)

Country Link
US (1) US9301955B2 (it)
EP (2) EP2659890A1 (it)
CA (1) CA2871815C (it)
CY (1) CY1117620T1 (it)
DK (1) DK2844253T3 (it)
ES (1) ES2569391T3 (it)
HR (1) HRP20160328T1 (it)
HU (1) HUE027353T2 (it)
IL (1) IL235358B (it)
PL (1) PL2844253T3 (it)
RS (1) RS54733B1 (it)
SI (1) SI2844253T1 (it)
SM (1) SMT201600102B (it)
WO (1) WO2013164204A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
US10231932B2 (en) * 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
FR3015977B1 (fr) * 2013-12-30 2016-01-01 Patrice Binay Chlorhydrate de tritoqualine sous forme cristallisee et procede d'obtention
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
FR3048883B1 (fr) * 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
FR3109524B1 (fr) 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) * 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
EP2037916A4 (en) 2006-04-07 2011-09-14 Mike Nicolaou PURE TRITOQUALINE ISOMERS
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
EP2170317A4 (en) 2007-02-12 2011-03-23 Mike Nicolaou TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
JP2011525194A (ja) * 2008-06-20 2011-09-15 キネメッド， インコーポレイテッド 線維性疾患または病態を治療するための組成物

Also Published As

Publication number Publication date
PL2844253T3 (pl) 2016-09-30
EP2659890A1 (en) 2013-11-06
US9301955B2 (en) 2016-04-05
ES2569391T3 (es) 2016-05-10
WO2013164204A1 (en) 2013-11-07
US20150133487A1 (en) 2015-05-14
CY1117620T1 (el) 2017-04-26
RS54733B1 (sr) 2016-10-31
IL235358A0 (en) 2014-12-31
DK2844253T3 (en) 2016-04-18
CA2871815A1 (en) 2013-11-07
HUE027353T2 (en) 2016-09-28
EP2844253B1 (en) 2016-03-23
SI2844253T1 (sl) 2016-09-30
EP2844253A1 (en) 2015-03-11
HRP20160328T1 (hr) 2016-06-03
IL235358B (en) 2019-09-26
CA2871815C (en) 2019-12-24

Similar Documents

Publication Publication Date Title
SMT201600102B (it) Tritoqualina per l’uso nel trattamento della fibrosi cistica
DK2999711T3 (da) Polymyxin-derivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
HK1222864A1 (zh) 的小分子調節劑和其使用方法
PT2664326T (pt) Terapia combinada para a fibrose quística
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
GB2515865B (en) Use of galactooligosaccharides in therapy
BR112014016471A8 (pt) uso de uma solução aquosa e chapa
HK1199393A1 (zh) 座椅式按摩器
DK3211410T3 (da) Elektrode og anvendelse deraf
FI20115640A0 (fi) Yhdistelmähoito
SMT201700072B (it) Utilizzo del pidotimod per il trattamento della psoriasi
SMT201600363B (it) Modafinil per l’uso nel trattamento di cocainomani
HK1186340A2 (en) Massager with symmetric massaging structure
SMT201700071B (it) Uso di pidotimod per il trattamento della dermatite atopica
ITRM20130465A1 (it) Metodo per la diagnosi in vitro di fibrosi polmonare/polmonite interstiziale idiopatica e uso di chelanti del ferro per il trattamento della fibrosi polmonare/polmonite interstiziale idiopatica.
SMT201600416B (it) Uso di sali di 3-carbossi-n-etil-n,n-dimetilpropan-1-amminio nel trattamento di malattie cardiovascolari
BR112015008353A2 (pt) uso cosmético e métodos cosméticos
HK1209033A1 (zh) 奧地帕西在治療黏多醣症病中的應用
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
FR3007434B1 (fr) Structure de cabanon en kit
FI20136034A (fi) Sauna